Alimera Sciences Inc (ALIM) Anticipated to Post Quarterly Sales of $11.27 Million

Alimera Sciences Inc (ALIM) Anticipated to Post Quarterly Sales of $11.27 Million

Equities analysts expect Alimera Sciences Inc (NASDAQ:ALIM) to announce sales of $11.27 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Alimera Sciences’ earnings. The lowest sales estimate is $10.90 million and the highest is $11.64 million. Alimera Sciences posted sales of $9.78 million in the same quarter last year, which would indicate a positive year over year growth rate of 15.2%. The company is expected to issue its next quarterly earnings report on Wednesday, November 7th.

On average, analysts expect that Alimera Sciences will report full-year sales of $43.51 million for the current financial year, with estimates ranging from $42.80 million to $44.21 million. For the next year, analysts expect that the company will post sales of $55.49 million, with estimates ranging from $50.70 million to $60.28 million. Zacks’ sales averages are an average based on a survey of research firms that cover Alimera Sciences.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings data on Monday, July 30th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06). The company had revenue of $10.92 million during the quarter, compared to analyst estimates of $10.78 million.

A number of equities research analysts have weighed in on ALIM shares. Cowen reiterated a “buy” rating and set a $3.00 price target on shares of Alimera Sciences in a research note on Wednesday, September 5th. HC Wainwright set a $3.00 price target on shares of Alimera Sciences and gave the stock a “buy” rating in a research note on Thursday, September 6th. Zacks Investment Research upgraded shares of Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research note on Thursday, August 2nd. Finally, B. Riley started coverage on shares of Alimera Sciences in a research note on Friday, June 29th. They set a “buy” rating and a $2.75 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $2.44.

ALIM opened at $0.94 on Wednesday. Alimera Sciences has a fifty-two week low of $0.74 and a fifty-two week high of $1.46. The company has a debt-to-equity ratio of -0.60, a quick ratio of 3.61 and a current ratio of 3.85. The firm has a market cap of $68.64 million, a price-to-earnings ratio of -3.34 and a beta of 1.51.

Hedge funds and other institutional investors have recently modified their holdings of the business. Stonepine Capital Management LLC lifted its holdings in shares of Alimera Sciences by 13.0% during the second quarter. Stonepine Capital Management LLC now owns 6,981,184 shares of the biopharmaceutical company’s stock valued at $6,830,000 after acquiring an additional 801,151 shares during the period. BlackRock Inc. lifted its holdings in shares of Alimera Sciences by 28.5% during the second quarter. BlackRock Inc. now owns 272,248 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 60,327 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Alimera Sciences by 20.8% during the second quarter. Renaissance Technologies LLC now owns 574,000 shares of the biopharmaceutical company’s stock valued at $562,000 after acquiring an additional 99,000 shares during the period. 51.85% of the stock is owned by institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Further Reading: Trading Penny Stocks

Get a free copy of the Zacks research report on Alimera Sciences (ALIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment